










## **CLAIMS**


### 1. An azabicyclic derivative represented by Formula I



an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

10 AZA represents an azacyclic group selected from





wherein

— represents an optional double bond;


5 n is 0, 1, 2 or 3;

m is 1 or 2; and

R' represents hydrogen or alkyl;

X' and X'' are absent (i.e. represent single (covalent) bonds); or

10 X' and X'', independently of one another, represent a linker selected from  
 -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



15 a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
 -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR''''; and

R''' represents hydrogen, alkyl or cyano; and


A' and A'', independently of one another, represent an aromatic monocyclic  
 20 and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or  
 more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy,  
 cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy,  
 carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic,  
 25 carbocyclic or heterocyclic group, which additional monocyclic or polycyclic,  
 carbocyclic or heterocyclic group may optionally be substituted one or more times with  
 substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl,  
 hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-  
 alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido,  
 30 sulfamoyl and phenyl; and

Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and L represents

a single (covalent) bond (i.e. L is absent); or

5 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; or

10 Y' and Y'', independently of one another, represent a linker selected from -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



15 and/or ; and/or

20 a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR'''; and


25 R''' represents hydrogen, alkyl or cyano; and

L represents

30 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl,

cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

2. An azabicyclic derivative of claim 1, being a quinuclidine derivative  
5 represented by Formula II



(II)


an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

10 ----- represents an optional double bond;

n is 1, 2 or 3;

X' and X'' are absent (i.e. represent single (covalent) bonds); or

15 X' and X'', independently of one another, represent a linker selected from  
-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
-CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,




20 a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
-NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR''''; and

R''' represents hydrogen, alkyl or cyano; and

A' and A'', independently of one another, represent an aromatic monocyclic  
25 and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or  
more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy,  
cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy,  
carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic,  
30 carbocyclic or heterocyclic group, which additional monocyclic or polycyclic,  
carbocyclic or heterocyclic group may optionally be substituted one or more times with  
substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl,


hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

- 5           Y' and Y" may be absent (i.e. represent single (covalent) bonds); and  
L represents  
a single (covalent) bond (i.e. L is absent); or  
a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; or  
10          Y' and Y", independently of one another, represent a linker selected from  
-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
-CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,  
15          and/or  and/or  ; and/or  
20          a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
-NR''-(C=Z')-NR''-; wherein  
25          Z' represents O, S or NR'''; and  
R''' represents hydrogen, alkyl or cyano; and  
L represents  
30          a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally  
35

be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

5

3. An azabicyclic derivative of claim 1, represented by Formula III



(III)


an enantiomer thereof, or a mixture of its enantiomers, or a 10 pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

R' represents hydrogen or alkyl;

n is 1, 2 or 3;

15

X' and X" are absent (i.e. represent single (covalent) bonds); or  
X' and X", independently of one another, represent a linker selected from  
-O-, -O-CH<sub>2</sub>- , -O-CH<sub>2</sub>-CH<sub>2</sub>- , -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>- , -S-CH<sub>2</sub>-CH<sub>2</sub>- ,  
-CH<sub>2</sub>- , -(C=CH<sub>2</sub>)- , -NH- , -N(alkyl)- , -(CO)- , -(CS)- ,



and/or ; and/or

20

a group of the formula -NR"--(CO)- , -NR"--(CO)-O- , -NR"--(SO<sub>2</sub>)- and  
-NR"--(C=Z')-NR"-; wherein

Z' represents O, S or NR"'; and

R"" represents hydrogen, alkyl or cyano; and

25

A' and A", independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic,

30

carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, 5 sulfamoyl and phenyl; and

Y' and Y" may be absent (i.e. represent single (covalent) bonds); and


L represents

a single (covalent) bond (i.e. L is absent); or

10 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, 15 carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, 20 carboxy, carbamoyl, amido, sulfamoyl and phenyl; or

Y' and Y", independently of one another, represent a linker selected from

-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, 25 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR'''; and


30 R''' represents hydrogen, alkyl or cyano; and

L represents

a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, 35 carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another

monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional  
 5 monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally  
 be substituted one or more times with substituents selected from the group  
 consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy,  
 hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl,  
 cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido,  
 sulfamoyl and phenyl.

4. An azabicyclic derivative of claim 1, represented by Formula IVa,



10


(IVa)

; an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

R' represents hydrogen or alkyl;

15

X' and X'' are absent (i.e. represent single (covalent) bonds); or  
 X' and X'', independently of one another, represent a linker selected from  
 -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



and/or ; and/or

20

a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
 -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR'''; and

R''' represents hydrogen, alkyl or cyano; and

25

A' and A'', independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic,

carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and


Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and

L represents

- 10 a single (covalent) bond (i.e. L is absent); or
- 15 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group
- 20 consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; or

Y' and Y'', independently of one another, represent a linker selected from

- 25 -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

- 30 Z' represents O, S or NR'''; and


R''' represents hydrogen, alkyl or cyano; and

L represents

- 35 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>,

carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alcoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alcoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

10 5. An azabicyclic derivative of claim 1, represented by Formula Va,




(Va)

;

an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

15 X' and X'' are absent (i.e. represent single (covalent) bonds); or  
 X' and X'', independently of one another, represent a linker selected from  
 -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



20 a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
 -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR''' ; and

R''' represents hydrogen, alkyl or cyano; and


25 A' and A'', independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alcoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alcoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy,  
 30 carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic,

carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

- Y' and Y" may be absent (i.e. represent single (covalent) bonds); and  
L represents  
a single (covalent) bond (i.e. L is absent); or  
10 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; or  
15 Y' and Y", independently of one another, represent a linker selected from  
- O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
20 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,  
25  
  
and/or ; and/or  
a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
-NR''-(C=Z')-NR''-; wherein  
Z' represents O, S or NR''; and  
30 R'' represents hydrogen, alkyl or cyano; and  
L represents  
a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another

monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional  
 5 monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally  
 be substituted one or more times with substituents selected from the group  
 consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy,  
 hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl,  
 cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido,  
 sulfamoyl and phenyl.

6. An azabicyclic derivative of claim 1, represented by Formula Vb,




10

(Vb)


; an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

15

X' and X" are absent (i.e. represent single (covalent) bonds); or  
 X' and X", independently of one another, represent a linker selected from  
 -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



and/or



; and/or

20

a group of the formula -NR"--(CO)-, -NR"--(CO)-O-, -NR"--(SO<sub>2</sub>)- and  
 -NR"--(C=Z')-NR"-; wherein

Z' represents O, S or NR"'; and

R''' represents hydrogen, alkyl or cyano; and

A' and A", independently of one another, represent an aromatic monocyclic  
 25 and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or  
 more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy,  
 cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy,  
 carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic,  
 30 carbocyclic or heterocyclic group, which additional monocyclic or polycyclic,  
 carbocyclic or heterocyclic group may optionally be substituted one or more times with

substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

5



Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and

L represents

a single (covalent) bond (i.e. L is absent); or

10 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another  
15 monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido,  
20 sulfamoyl and phenyl; or

25 Y' and Y'', independently of one another, represent a linker selected from -O-, -O-CH<sub>2</sub>- , -O-CH<sub>2</sub>-CH<sub>2</sub>- , -S-, -SO-, -SO<sub>2</sub>- , -CH<sub>2</sub>- , -S-CH<sub>2</sub>-CH<sub>2</sub>- , -CH<sub>2</sub>- , -(C=CH<sub>2</sub>)- , -NH- , -N(alkyl)- , -(CO)- , -(CS)- ,



and/or ; and/or

25 a group of the formula -NR''-(CO)- , -NR''-(CO)-O- , -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''- ; wherein

Z' represents O, S or NR''' ; and

R''' represents hydrogen, alkyl or cyano; and

30


L represents

30 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional

monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

5


7. An azabicyclic derivative of claim 1, represented by Formula Vc,



(Vc)

10 an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

X' and X'' are absent (i.e. represent single (covalent) bonds); or  
 X' and X'', independently of one another, represent a linker selected from  
 15 -O-, -O-CH<sub>2</sub>- , -O-CH<sub>2</sub>-CH<sub>2</sub>- , -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>- , -S-CH<sub>2</sub>-CH<sub>2</sub>- ,  
 -CH<sub>2</sub>- , -(C=CH<sub>2</sub>)- , -NH-, -N(alkyl)- , -(CO)- , -(CS)-,



a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
 -NR''-(C=Z')-NR''-; wherein

20 Z' represents O, S or NR''' ; and

R''' represents hydrogen, alkyl or cyano; and

A' and A'', independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or  
 25 more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with  
 30

substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

5


Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and  
L represents

a single (covalent) bond (i.e. L is absent); or

10 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another  
15 monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; or  
20

Y' and Y'', independently of one another, represent a linker selected from

-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
-CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



25

and/or ; and/or

a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR'''; and

R'' represents hydrogen, alkyl or cyano; and

30

L represents


a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional

35

monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alcoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

5


8. An azabicyclic derivative of claim 1, represented by Formula VIa,



(VIa)

10 an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

X' and X'' are absent (i.e. represent single (covalent) bonds); or  
X' and X'', independently of one another, represent a linker selected from  
15 -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
-CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,





a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
-NR''-(C=Z')-NR''-; wherein

20 Z' represents O, S or NR''; and

R'' represents hydrogen, alkyl or cyano; and

A' and A'', independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or  
25 more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alcoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic,  
30 carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl,


hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

- 5            Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and  
 L represents  
     a single (covalent) bond (i.e. L is absent); or  
     a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; or  
 10          Y' and Y'', independently of one another, represent a linker selected from  
     -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
     -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,  
 15          and/or  and/or  ; and/or  
 20          a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
     -NR''-(C=Z')-NR''-; wherein  
     Z' represents O, S or NR''; and  
     R'' represents hydrogen, alkyl or cyano; and  
 25          L represents  
     a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally  
 30  
 35

be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

5

9. An azabicyclic derivative of claim 1, represented by Formula VII,



(VII)

an enantiomer thereof, or a mixture of its enantiomers, or a  
10 pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

R' represents hydrogen or alkyl;

n is 1, 2 or 3;


15 m is 1 or 2;

X' and X'' are absent (i.e. represent single (covalent) bonds); or

X' and X'', independently of one another, represent a linker selected from

-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,

20 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



and/or ; and/or



a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
-NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR''''; and

25 R''' represents hydrogen, alkyl or cyano; and

A' and A'', independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy,


carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl,  
 5 hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

- Y' and Y" may be absent (i.e. represent single (covalent) bonds); and  
 10 L represents  
     a single (covalent) bond (i.e. L is absent); or  
     a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 15 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional  
 20 monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; or  
 25 Y' and Y", independently of one another, represent a linker selected from  
     -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
     -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,  
 and/or  ; and/or  
     a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
 30 -NR''-(C=Z')-NR''-; wherein  
     Z' represents O, S or NR''; and  
     R'' represents hydrogen, alkyl or cyano; and  
 L represents  
     a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 35 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy,

5       cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

10

10. An azabicyclic derivative of claim 1, represented by Formula VIII,



(VII)

an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

15

R' represents hydrogen or alkyl:

$n$  is 1, 2 or 3:


m is 1 or 2;

20

X' and X'' are absent (i.e. represent single (covalent) bonds); or

$X'$  and  $X''$ , independently of one another, represent a linker selected from

-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



25


a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR"; and


R<sup>'''</sup> represents hydrogen, alkyl or cyano; and

A' and A'', independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 5 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with  
 10 substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

15 Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and  
 L represents  
 a single (covalent) bond (i.e. L is absent); or  
 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 20 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido,  
 25 sulfamoyl and phenyl;  
 30 or  
 Y' and Y'', independently of one another, represent a linker selected from  
 -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



and/or



; and/or

35 a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein


Z' represents O, S or NR''; and

R''' represents hydrogen, alkyl or cyano; and  
 L represents

5 a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional 10 monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

15

11. An azabicyclic derivative of claim 1, represented by Formula IX,




(IX)

an enantiomer thereof, or a mixture of its enantiomers, or a 20 pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

R' represents hydrogen or alkyl;

X' and X'' are absent (i.e. represent single (covalent) bonds); or  
 25 X' and X'', independently of one another, represent a linker selected from -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,




a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and  
 30 -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR'''; and


R''' represents hydrogen, alkyl or cyano; and

A' and A'', independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 5 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with  
 10 substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

15 Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and  
 L represents  
     a single (covalent) bond (i.e. L is absent); or  
     a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with  
 20 substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl;  
 25 or  
 30 Y' and Y'', independently of one another, represent a linker selected from  
     -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
     -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



and/or



; and/or


35 a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR'''; and

R<sup>'''</sup> represents hydrogen, alkyl or cyano; and  
 L represents

5 a group A<sup>'''</sup> which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 10 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional  
 15 monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

12. An azabicyclic derivative of claim 1, represented by Formula X,




(X)

an enantiomer thereof, or a mixture of its enantiomers, or a  
 20 pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

R' represents hydrogen or alkyl;

X' and X'' are absent (i.e. represent single (covalent) bonds); or  
 25 X' and X'', independently of one another, represent a linker selected from  
 -O-, -O-CH<sub>2</sub>- , -O-CH<sub>2</sub>-CH<sub>2</sub>- , -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>- , -S-CH<sub>2</sub>-CH<sub>2</sub>- ,  
 -CH<sub>2</sub>- , -(C=CH<sub>2</sub>)- , -NH- , -N(alkyl)- , -(CO)- , -(CS)- ,




30 a group of the formula -NR''-(CO)- , -NR''-(CO)-O- , -NR''-(SO<sub>2</sub>)- and  
 -NR''-(C=Z')-NR''- ; wherein

Z' represents O, S or NR"'; and  
 R''' represents hydrogen, alkyl or cyano; and


- A' and A'', independently of one another, represent an aromatic monocyclic  
 5 and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or  
 more times with substituents selected from the group consisting of alkyl, cycloalkyl,  
 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy,  
 cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy,  
 carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic,  
 10 carbocyclic or heterocyclic group, which additional monocyclic or polycyclic,  
 carbocyclic or heterocyclic group may optionally be substituted one or more times with  
 substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl,  
 hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-  
 alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido,  
 15 sulfamoyl and phenyl; and

Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and  
 L represents

- a single (covalent) bond (i.e. L is absent); or  
 20 a group A''' which represents a monocyclic or polycyclic, carbocyclic or  
 heterocyclic group, optionally substituted one or more times with  
 substituents selected from the group consisting of alkyl, cycloalkyl,  
 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy,  
 cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>,  
 carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another  
 25 monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional  
 monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally  
 be substituted one or more times with substituents selected from the group  
 consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy,  
 30 hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl,  
 cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido,  
 sulfamoyl and phenyl; or  
 Y' and Y'', independently of one another, represent a linker selected from  
 -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,  
 35 -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



and/or



; and/or

a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR''; and

R'' represents hydrogen, alkyl or cyano; and

5 L represents


a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

10

15

20

13. An azabicyclic derivative of claim 1, represented by Formula XI,



an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

25

R' represents hydrogen or alkyl;


X' and X'' are absent (i.e. represent single (covalent) bonds); or

X' and X'', independently of one another, represent a linker selected from

-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-,

30

-CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



and/or ; and/or

a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR''; and

R'' represents hydrogen, alkyl or cyano; and

5

A' and A'', independently of one another, represent an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, 10 cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, 15 hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; and

Y' and Y'' may be absent (i.e. represent single (covalent) bonds); and


20 L represents

a single (covalent) bond (i.e. L is absent); or

a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl; or

35 Y' and Y'', independently of one another, represent a linker selected from

-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



a group of the formula -NR"--(CO)-, -NR"--(CO)-O-, -NR"--(SO<sub>2</sub>)- and -NR"--(C=Z')-NR"-; wherein

Z' represents O, S or NR"'; and

5 R''' represents hydrogen, alkyl or cyano; and

L represents

a group A''' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl,

10 cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional

15 monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

20


14. The azabicyclic derivative of either one of claims 1-2, wherein ----- represents a single (covalent) bond.

25 15. The azabicyclic derivative of any one of claims 1, 2, 3, 9 and 10, wherein n is 1, 2 or 3.

16. The azabicyclic derivative of any one of claims 1, 9 and 10, wherein m is 1 or 2.

30

17. The azabicyclic derivative of any one of claims 1-16, wherein X' and X'' are absent (i.e. represent single (covalent) bonds); or X' and X'', independently of one another, represent a linker selected from -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



35

a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR''"; and

R''' represents hydrogen, alkyl or cyano.

5

18. The azabicyclic derivative of claim 17, wherein


X' and X" are absent (i.e. represent single (covalent) bonds).

10


19. The azabicyclic derivative of claim 16, wherein

X' and X", independently of one another, represent a linker selected from

-O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



and/or



; and/or

15

a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein

Z' represents O, S or NR''"; and

R''' represents hydrogen, alkyl or cyano.

25

20. The azabicyclic derivative of claim 19, wherein X' and X", independently of one another, represent a linker selected from -O-, -O-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -NH-(CO)-NH- and/or -NH-(CO)-O-.

21. The azabicyclic derivative of claim 17, wherein

X' and X" are absent (i.e. represent single (covalent) bonds); or

X' and X" represent -O- or -O-CH<sub>2</sub>-, or

X' represents -O- or -O-CH<sub>2</sub>-, and

X" represents -NH-(CO)-NH- or -NH-(CO)-O-.

30

22. The azabicyclic derivative of any one of claims 1-21, wherein L represents a single (covalent) bond (i.e. L is absent).

23. The azabicyclic derivative of any one of claims 1-22, wherein Y' and Y" are absent (i.e. represent single (covalent) bonds).

35


24. The azabicyclic derivative of claim 23, wherein L represents a single (covalent) bond (i.e. L is absent); or

a group A'' which represents an aromatic monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

25. The azabicyclic derivative of claim 24, wherein A'' represents a phenyl, naphthyl, pyridyl, thienyl, furanyl, pyridazinyl or thiazolyl group.

15

26. The azabicyclic derivative of any one of claims 1-21, wherein Y' and Y'', independently of one another, represent a linker selected from -O-, -O-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -(C=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -(CO)-, -(CS)-,



20

and/or ; and/or  
a group of the formula -NR''-(CO)-, -NR''-(CO)-O-, -NR''-(SO<sub>2</sub>)- and -NR''-(C=Z')-NR''-; wherein  
Z' represents O, S or NR'''; and  
R''' represents hydrogen, alkyl or cyano.

25

27. The azabicyclic derivative of claim 26, wherein L represents a group A'' which represents a monocyclic or polycyclic, carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl and phenyl.

28. The azabicyclic derivative of claim 27, wherein A'' represents a phenyl, naphthyl, pyridyl, thienyl, furanyl, pyridazinyl or thiazolyl group.

5           29. The azabicyclic derivative of either one of claims 1-2, wherein

----- represents a single (covalent) bond;

n is 2;

10           X' and X'' are absent (i.e. represent single (covalent) bonds); or  
X' and X'', independently of one another, represent -O-, -S-, -SO- or -NH-;  
and

15           A' and A'' represent phenyl, pyridyl, thienyl, furanyl, pyridazinyl and/or  
thiazolyl; and

Y', Y'' and L represent single (covalent) bonds.

20           30. The azabicyclic derivative of claim 29, which is  
2,2'-Bis-((±)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[5,5']-bithiazolyl;  
2,2'-Bis-((±)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[5,5']-bifuranyl;  
6,6'-Bis-((±)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[3,3']-bipyridinyl;  
6,6'-Bis-((±)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[3,3']-bipyridazinyl; or  
25           6-[4-(1-Aza-bicyclo[2.2.2]oct-3-yloxy)-phenyl]-pyridazin-3-ol-(1-aza-  
bicyclo[2.2.2]oct-3-yl);  
or an enantiomer thereof, or a pharmaceutically-acceptable addition salt  
thereof, or an onium salt thereof.

30           31. The azabicyclic derivative of either one of claims 1 and 7, wherein

X' and X'' are absent (i.e. represent single (covalent) bonds); or  
X' and X'' represent -O-, -S-, -SO-, -NH-, or -(CO)-; and

35           A' and A'' represent phenyl, pyridyl, thienyl, furanyl, pyridazinyl and/or  
thiazolyl; and

Y', Y'' and L represent single (covalent) bonds; or  
Y' and Y'' represent -O-, -S-, -SO- or -NH-; and

L represents a phenyl group.

32. The azabicyclic derivative of claim 31, which is  
6,6'-Bis-[1,4]-diaza-bicyclo[3.2.2]nonan-1-yl-[3,3']-bipyridazinyl;  
5 1,2-Di-[6-(1,4-diaza-bicyclo[3.2.2]nonan-4-yl)-pyridazin-3-yl-thio]-benzene;  
or  
10 1,3-Di-[6-(1,4-diaza-bicyclo[3.2.2]nonan-4-yl)-pyridazin-3-yl-thio]-benzene;  
or an enantiomer thereof, or a pharmaceutically-acceptable addition salt  
thereof, or an onium salt thereof.
33. A pharmaceutical composition comprising a therapeutically effective  
amount of an azacyclic derivative of any one of claims 1-32, or a pharmaceutically-  
acceptable addition salt thereof.
- 15 34. Use of an azacyclic derivative of any one of claims 1-32, or a  
pharmaceutically-acceptable addition salt thereof, for the manufacture of a  
pharmaceutical composition/medicament for the treatment, prevention or alleviation of  
a disease or a disorder or a condition of a mammal, including a human, which disease,  
disorder or condition is responsive to modulation of cholinergic receptors and/or  
20 monoamine receptors.
35. The use according to claim 34, wherein the disease, disorder or  
condition relates to the central nervous system.
- 25 36. The use according to claim 35, wherein the disease, disorder or  
condition is anxiety, cognitive disorders, learning deficit, memory deficits and  
dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity  
disorder (ADHD), Parkinson's disease, Huntington's disease, Amyotrophic Lateral  
Sclerosis, Gilles de la Tourette's syndrome, psychosis, depression, mania, manic  
30 depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders,  
eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy,  
nociception, AIDS-dementia, senile dementia, peripheral neuropathy, autism, dyslexia,  
tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social  
phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual  
35 syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism,  
trichotillomania and jet-lag.
37. The use according to claim 34, wherein the disease, disorder or  
condition are associated with smooth muscle contractions, including convulsive

disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation and erectile difficulty.

38. The use according to claim 34, wherein the disease, disorder or  
5 condition is related to the endocrine system, such as thyrotoxicosis,  
pheochromocytoma, hypertension and arrhythmias.

39. The use according to claim 34, wherein the disease, disorder or  
condition is a neurodegenerative disorders, including transient anoxia and induced  
10 neuro-degeneration.

40. The use according to claim 34, wherein the disease, disorder or  
condition is an inflammatory disorder, including inflammatory skin disorders such as  
acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis and  
15 diarrhoea.

41. The use according to claim 34, wherein the disease, disorder or  
condition is mild, moderate or even severe pain of acute, chronic or recurrent  
character, pain caused by migraine, postoperative pain, phantom limb pain,  
20 neuropathic pain, chronic headache, central pain, pain related to diabetic neuropathy,  
to post therapeutic neuralgia, or to peripheral nerve injury.

42. The use according to claim 34, wherein the disease, disorder or  
condition is associated with withdrawal symptoms caused by termination of use of  
25 addictive substances, including nicotine containing products such as tobacco, opioids  
such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like  
drugs and alcohol.

43. A method of treatment, prevention or alleviation of a disease or a  
30 disorder or a condition of a living animal body, including a human, which disorder,  
disease or condition is responsive to modulation of cholinergic receptors and/or  
monoamine receptors, which method comprises the step of administering to such a  
living animal body in need thereof a therapeutically effective amount of an azacyclic  
derivative of any one of claims 1-32.